Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01908257 · ClinicalTrials.gov registry record · Phase 1
Lesinurad Interaction Study With Ranitidine
A Phase 1 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01908257 is a Phase 1 study that has completed, run by Ardea Biosciences. The registered enrollment target is 16 participants.
The verdict
NCT01908257, a Phase 1 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a drug-drug interaction study in healthy volunteers to evaluate the potential pharmacokinetic (PK) effects of ranitidine on lesinurad.
Interventions
- DRUG lesinurad 400 mg
- DRUG ranitidine 150 mg
- DRUG lesinurad 400 mg + ranitidine 150 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-07 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01908257
The ClinicalTrials.gov registry entry for NCT01908257 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which lesinurad 400 mg is the first listed.
NCT01908257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01908257 about?
NCT01908257 is a clinical study titled "Lesinurad Interaction Study With Ranitidine". This is a drug-drug interaction study in healthy volunteers to evaluate the potential pharmacokinetic (PK) effects of ranitidine on lesinurad.
What is the current status of trial NCT01908257?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2013-07. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01908257?
The interventions under investigation include: lesinurad 400 mg (DRUG), ranitidine 150 mg (DRUG), lesinurad 400 mg + ranitidine 150 mg (DRUG).
Who is sponsoring clinical trial NCT01908257?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.